RT @Stiddyo: #OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16week
Tweet Content
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks
Primary endpoint ACR20
12mg: 62.7%
6mg: 52.9%
PLC: 31.8%
+ well tolarated: no serious adverse events
#EULAR2021 @RheumNow https://t.co/6SFqWd79db
Show on Archive Page
On
Display in Search Results
On
PDQ
Off